Quick Answer
Wegovy and Ozempic contain the same active ingredient — semaglutide — but they are different FDA approvals with distinct indications.
- Wegovy is approved for chronic weight management in adults with obesity or overweight
- Ozempic is approved for type 2 diabetes control
- Wegovy reaches a maximum dose of 2.4 mg weekly; Ozempic maxes at 2.0 mg weekly
- Insurance coverage differs significantly based on indication
- Many telehealth providers prescribe Ozempic off-label for weight loss
Key Differences at a Glance
| Attribute | Wegovy | Ozempic |
|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide |
| FDA Indication | Chronic weight management | Type 2 diabetes |
| Maximum Dose | 2.4 mg weekly | 2.0 mg weekly |
| Dosing Schedule | Weekly injections; 16-week titration | Weekly injections; 30-week titration |
| Typical Insurance Coverage | Often not covered (cosmetic classification) | More likely covered (medical necessity) |
| Approximate Cost (Cash) | $900–$1,500/month at maintenance | $700–$1,200/month (varies by provider) |
| Off-Label Use | Not needed; on-label approved | Used off-label for weight loss by many providers |
Why the Same Drug Has Two Names
Novo Nordisk, the pharmaceutical company that manufactures semaglutide, pursued separate FDA approvals for two distinct clinical indications. This strategy—common in the pharmaceutical industry—allows the company to market the same active ingredient to different patient populations with tailored dosing, instructions, and labeling.
Wegovy was developed specifically for weight management, with a higher maximum dose (2.4 mg) and a faster titration schedule (16 weeks to reach therapeutic dose) compared to Ozempic's diabetes protocol. The FDA reviews each indication separately based on clinical trial data, so both are technically the same compound but with legally distinct approvals.
This separation also affects how insurance treats the medications: Ozempic is classified as a diabetes treatment (often covered), while Wegovy is classified as a weight loss medication (often excluded from coverage). The legal distinction matters financially even though the pharmacology is identical.
Dosing Comparison: Ozempic vs Wegovy
Ozempic Dosing (Diabetes Management)
Ozempic is prescribed starting at 0.25 mg weekly and titrated every 4 weeks up to the maximum of 2.0 mg weekly. The typical maintenance dose for diabetes control is 0.5–1.0 mg weekly. The slower, longer titration (30 weeks) is designed to allow the body to adjust while focusing on blood sugar control.
Wegovy Dosing (Weight Management)
Wegovy begins at 0.25 mg weekly and is titrated every 4 weeks through these doses: 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg. Most patients reach the maximum dose within 16 weeks. The faster approach to higher doses reflects the indication: maximizing weight loss effect rather than gradual diabetes management.
Clinical Implications
The 0.4 mg difference in maximum dose (2.4 mg for Wegovy vs 2.0 mg for Ozempic) reflects clinical trial data showing additional weight loss benefit at the higher dose. When Ozempic is prescribed off-label for weight loss, some providers titrate it to 2.4 mg to match Wegovy's therapeutic dose, while others remain at the standard 2.0 mg diabetes maximum.
Weight Loss Results: Clinical Evidence
Both Wegovy and Ozempic (at equivalent doses) produce similar weight loss outcomes in clinical trials because they contain the same active compound. The landmark STEP trial for Wegovy showed participants lost approximately 15% of body weight over 68 weeks at the 2.4 mg dose. Real-world results vary based on individual factors like starting weight, diet adherence, and exercise.
Ozempic's diabetes trials were not designed to measure weight loss as a primary endpoint, but secondary analyses show weight loss similar to Wegovy when dosed comparably. When prescribed off-label for weight loss by telehealth providers, the weight loss efficacy is equivalent to Wegovy if dosing is equivalent.
Important context: GLP-1 medications are not "magic." Weight loss depends on a combination of the medication's appetite-suppressing effect, consistent calorie deficit, nutrition quality, physical activity, and lifestyle habits. Medications in this class produce 5–20% body weight reduction on average, with outcomes distributed across a wide range.
Insurance Coverage: The Critical Difference
Wegovy is often classified as a "cosmetic" or elective medication by insurance companies, meaning most standard health plans will not cover it. Some employer-sponsored plans, managed care networks, or specialized weight loss programs may offer coverage, but it's less common. Out-of-pocket costs are typically $900–$1,500 monthly at maintenance dosing.
Ozempic is approved for a medical condition (type 2 diabetes) and is more likely to be covered by insurance plans. Coverage varies widely, but diabetes medications generally receive more favorable treatment than weight loss drugs. When covered, copays or coinsurance are typically much lower than paying cash for Wegovy.
This distinction is why some patients and providers prefer Ozempic off-label: it has better insurance coverage and lower cost. However, prescribing off-label carries clinical considerations (see "How Providers Navigate Off-Label Prescribing" below).
Many GLP-1 telehealth providers offer both medications at discounted prices ($300–$800 monthly) because they negotiate directly with pharmacies or operate their own pharmacies. Some programs include medication in a flat monthly membership fee. See Wegovy cost comparison and how to get GLP-1 online for provider-specific pricing.
How Providers Navigate Off-Label Prescribing
Off-label prescribing—using an FDA-approved medication for an indication other than the one it was approved for—is legal and common in medicine. Ozempic prescribed for weight loss is an example of off-label use. Providers may do this because:
- The medication works pharmacologically for the condition, even if formal trials weren't conducted
- Insurance coverage is better for the approved indication
- Cost is lower due to generic or negotiated pricing
However, off-label prescribing carries some caveats. The prescriber must be aware of the risks, monitor the patient appropriately, and the patient must consent. Marketing departments cannot promote off-label use, but doctors can prescribe it. When choosing between Wegovy (on-label) and Ozempic (off-label for weight loss), weigh the clinical evidence (equivalent) against the practical factors (cost, insurance).
Which Medication Should You Choose?
If you're considering GLP-1 therapy for weight loss, the choice between Wegovy and Ozempic depends on:
- Insurance coverage: If your plan covers Ozempic for diabetes or off-label weight loss, that is likely the most cost-effective option.
- Out-of-pocket budget: Telehealth providers often price both equivalently; compare their rates directly.
- Dose availability: If your provider stocks Wegovy's maximum dose (2.4 mg), that might be clinically preferable if pursuing aggressive weight loss. Some providers may offer only lower Ozempic doses.
- Provider preference: Ask your prescriber which they recommend based on your health profile and weight loss goals. The clinical difference is minimal; the practical difference (cost) is substantial.
See GLP1Authority's program reviews for specific medication offerings at each platform.
Side Effects and Safety: Identical
Because Wegovy and Ozempic contain the same molecule at comparable doses, side effect profiles are nearly identical. Common side effects include nausea, vomiting, constipation, and diarrhea—most pronounced in the first 1–2 weeks of a dose increase and typically resolve. Serious side effects (acute kidney injury, pancreatitis, thyroid tumor risk) are rare and monitored by healthcare providers.
The main contraindication is a personal or family history of thyroid cancer (medullary thyroid carcinoma) or multiple endocrine neoplasia type 2 (MEN2). Your prescriber will screen for this before recommending either medication.
Frequently Asked Questions
Can I switch between Wegovy and Ozempic?
Yes. Both contain semaglutide, so switching is straightforward from a pharmacological perspective. The main consideration is whether your prescriber and pharmacy have both in stock. Many telehealth providers can prescribe either based on availability, insurance, or cost.
Is one faster-acting than the other?
No. Both have identical onset and duration of action. Results appear over weeks to months as doses increase and accumulate in your system.
Will Ozempic stop working if I use it off-label?
No. Off-label use doesn't affect efficacy. The medication works identically whether it's prescribed on-label (Wegovy for weight loss) or off-label (Ozempic for weight loss).
Will insurance cover Wegovy if I'm not diabetic?
Wegovy is approved for weight management regardless of diabetes status, but insurance coverage varies. Many standard health plans do not cover weight loss medications, treating them as cosmetic. Some employers and managed care plans cover Wegovy. Check your specific plan or use a GLP-1 telehealth provider if insurance doesn't cover it.
Which telehealth providers prescribe which medication?
Many GLP-1 telehealth providers offer both Wegovy and Ozempic (often off-label for weight loss). Some programs offer only Wegovy. Review provider pages on GLP1Authority to see which medications each platform prescribes and at what cost.